iSpecimen Inc Rises 29.66% as It Crosses Above 20-Day SMA
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 28 Nov 25
Source: NASDAQ.COM
iSpecimen Inc. experienced a significant price increase of 29.66% today, crossing above the 20-day simple moving average (SMA). This technical movement indicates a potential bullish trend for the stock.
The rise in stock price comes amid positive market sentiment, with the Nasdaq-100 (QQQ) up 0.50% and the S&P 500 (SPY) up 0.43%. Such market conditions often contribute to increased investor confidence and buying activity.
Investors may view this upward movement as a signal of strength, potentially attracting further interest in iSpecimen Inc. as it continues to gain traction in the market.
Analyst Views on ISPC
About ISPC
iSpecimen Inc. is a technology-driven company. The Company addresses a critical challenge, which focuses on connecting life science researchers who need human biofluids, tissues, and living cells (biospecimens) for their research. The Company’s iSpecimen Marketplace platform is designed to solve this problem and transform the biospecimen procurement process to accelerate medical discovery. Its technology consolidates the biospecimen buying experience in a single, online marketplace that brings together healthcare providers who have biospecimens and researchers across industry, academia, and government institutions who need them. In addition to providing the technology platform to connect researchers and healthcare providers, the Company handles all marketing, sales, contracting, and compliance functions across both sides of the marketplace. The iSpecimen Marketplace technology comprises four functional areas: search, workflow, data and administrative, compliance and reporting.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
